The role of fenofibrate in clinical practice

Diabetes and Vascular Disease Research

Volumn 4, Issue SUPPL. 3, 2007, Pages

  Zambon, Alberto ^a   Cusi, Kenneth ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Cardiovascular disease; Combination therapy; Dyslipidaemia; Fenofibrate; Metabolic syndrome; Microvascular disease; Type 2 diabetes

Indexed keywords

ATORVASTATIN; FENOFIBRATE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIOGLITAZONE; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DISEASE COURSE; DRUG TOLERANCE; FATTY LIVER; HUMAN; LIPID METABOLISM; METABOLIC SYNDROME X; MONOTHERAPY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; RETINOPATHY;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FATTY LIVER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; LIVER; METABOLIC SYNDROME X; PPAR ALPHA; PROCETOFEN; RISK FACTORS; TREATMENT OUTCOME;

EID: 35548979848     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2007.053     Document Type: Conference Paper

References (50)

1. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Croup. Lancet 1998;352:837-53.
2. UKPDS report number 38. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:703-13.
3. Turner RC, Millns H, Neil HAW et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998;316:823-8.
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 2002;106:3143-421.
5. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 2006;29(suppl 1):S4-S42.
6. Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. A Scientific Statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115:114-26.
7. Ryden L, Standl E, Bartnik M et al., on behalf of the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary. Eur Heart J 2007;28:88-136.
8. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366: 1267-78.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
10. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
11. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
12. Sever PS, Poulter NR, Dahlöf B et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes. Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care 2005;28:1151-7.
13. Knopp RH, D'Emden M, Smilde JG et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular endpoints in subjects with type 2 diabetes. The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-lnsulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care 2006;29:1478-85.
14. Jacobson TA, Case CC, Roberts S et al. Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes Obes Metab 2004;6:353-62.
15. Costa J, Borges M, David C, Vas Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006;332:1115-24.
16. Ballantyne CM, Herd A, Ferlic LL et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999;99:736-43.
17. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003;171:1-13.
18. Frick MH, Elo O, Haapa K et al. Helsinki Heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
19. Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85:37-45.
20. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410- 18.
21. Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002;162:2597-604.
22. The BIP Study group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7.
23. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005;165:1154-61.
24. Keech A, Simes RJ, Barter P et al. The FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
25. Kashyap S, Belfort R, Gastaldelli A et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003;52:2461-74.
26. Alvarsson M, Grill V. Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders. Scand J Clin Lab Invest 1996;56:563-70.
27. Kelly JJ, Lawson JA, Campbell LV et al. Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens 2000;14:567-72.
28. Poynten AM, Can SK, Kriketos AD et al. Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism 2003;52:699- 704.
29. Vega GL, Cater NB, Meguro S, Grundy SM. Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol 2005;95:1309-13.
30. Belfort R, Berria R, DeFronzo R, Cusi K. Fenofibrate improves the atherogenic lipid profile and markers of vascular inflammation independent of changes in insulin sensitivity in hypertriglyceridemic subjects with the metabolic syndrome. Diabetologia 2004;47(suppl 1): A620 [abstract].
31. Manuel DG, Schultz SE. Health-related quality of life and health-adjusted life expectancy of people with diabetes in Ontario, Canada, 1996-1997. Diabetes Care 2004;27:407-14.
32. Wandell PE. Quality of life of patients with diabetes mellitus. An overview of research in primary health care in the Nordic countries. Scand J Prim Health Care 2005;23:68-74.
33. Ansquer JC, Foucher C, Rattier S et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005;45:485-93.
34. Keech A. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Atherosclerosis Supplements 2006;7:342 [abstract].
35. Belfort R, Harrison S, Brown K et al. A placebo-controlled trial of pioglitazone in patients with non-alcoholic steatohepatitis. N Engl J Med 2006;355:2297-307.
36. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
37. Athyros VG, Papageorgiou AA, Athyrou W et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25:1198-202.
38. ACCORD Study Group, Buse JB, Bigger JT, Byington RP. Action to Control Cardiovascular Risk in Diabetes trial: design and methods. Am J Cardiol 2007;99(suppl 12A):21i-33i.
39. Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004;116:408-16.
40. Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol 2004;94:935-8.
41. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95: 120-2.
42. Prueksaritanont T, Subramanian R, Fang X et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002;30:505-12.
43. Backman JT, Kyrklund C, Kivisto KT et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000;68:122-9.
44. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003;73:538-44.
45. Schneck DW, Birmingham BK, Zalikowski JA et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004;75:455-63.
46. Bergman AJ, Murphy G, Burke J et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004;44:1054-62.
47. Gustavson LE, Schweitzer SM, Koehne-Voss S et al. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3α-hydroxy isomeric metabolite. J Clin Pharmacol 2005;45:947-53.
48. Pan WJ, Gustavson LE, Achari R et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 2000;40:316-23.
49. Martin PD, Dane AL, Schneck DW et al. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003;25:459-71.
50. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007;99(suppl):3C-18C.